Spyre Therapeutics Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Spyre Therapeutics Inc (SYRE) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Spyre Therapeutics Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 6M vs 349,399M combined for tracked competitors (0.0% combined share).
- Scale: Spyre Therapeutics Inc ranks #20 of 544 companies by market capitalization in the Major Pharmaceutical Preparations industry, holding 0.5% of industry market cap.
- Peer differentiation: Revenue per employee of $0.06M compares with $0.95M for the peer group (0.1x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
Spyre Therapeutics Inc vs. its Competitors, Q2 2026
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Spyre Therapeutics Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Spyre Therapeutics Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (9) | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (8) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Spyre Therapeutics Inc's competitor groups requires a Commercial License.
Spyre Therapeutics Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Spyre Therapeutics Inc | - | - | - | No |
| Competitors combined (78) | ||||
| High-Confidence Competitors (12) | ||||
| Similar-Size Competitors (9) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
SYRE Stock Performance relative to its Competitors
SYRE Stock Performance relative to High-Confidence Competitors
SYRE Stock Performance relative to Similar-Size Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Adlai Nortye Ltd | 282.9% | Outperformed |
| 2 | Erasca Inc | 282.9% | Outperformed |
| 3 | Gossamer Bio Inc | 282.9% | Outperformed |
| 4 | Prelude Therapeutics Inc | 282.9% | Outperformed |
| 5 | Day One Biopharmaceuticals Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Spyre Therapeutics Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Spyre Therapeutics Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Spyre Therapeutics Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Spyre Therapeutics Inc | - | 5.81 |
| Eli Lilly And Company | 1,058,837.89 | 79,665.80 |
| Beone Medicines Ltd | 552,467.82 | 6,128.24 |
| Abbvie Inc | 471,581.88 | 64,386.00 |
| Novartis Ag | 287,150.40 | 56,674.00 |
| Astrazeneca Plc | 259,526.30 | 58,739.00 |
| SUBTOTAL | 3,419,085.79 | 467,140.01 |
Sign in to see all competitors of Spyre Therapeutics Inc .
Sources: Spyre Therapeutics Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Spyre Therapeutics Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Spyre Therapeutics Inc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Bristol Myers Squibb | Named by the company | 85% |
| Shattuck Labs Inc | Named by the company | 85% |
| Johnson & Johnson | Named by the company | 85% |
| Roivant | Named by the company | 85% |
| Absci Corp | Named by the company | 85% |
| Erytech Pharma SA | Named by the company | 85% |
| Pfizer | Named by the company | 85% |
| Teva | Named by the company | 85% |
| AbbVie | Named by the company | 85% |
| Lilly | Named by the company | 85% |
| Sanofi | Named by the company | 85% |
| Agomab Therapeutics Nv | Named by the company | 85% |
| Horizon Therapeutics | Named by the company | 85% |
| Roche | Named by the company | 85% |
| Merck | Named by the company | 85% |
| Takeda | Named by the company | 85% |
| Novabridge Biosciences | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Spyre Therapeutics Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Spyre Therapeutics Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Eli Lilly And Company | Reportable 100.00 % |
| Amgen Inc | Reportable 100.00 % |
| Pfizer Inc | U.S. Commercial Division 52.92 % |
| Teva Pharmaceutical Industries Limited | United States Segment 41.09 % |
| Viatris Inc | Developed Markets 57.61 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Spyre Therapeutics Inc .
Spyre Therapeutics Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Spyre Therapeutics Inc | - | 56,912 | -1,754,098 |
| Eli Lilly And Company | 1,058,838 | 1,593,316 | 534,224 |
| Beone Medicines Ltd | 552,468 | 510,686 | 54,642 |
| Abbvie Inc | 471,582 | 1,129,579 | 110,807 |
| Novartis Ag | 287,150 | 752,973 | 185,566 |
| Astrazeneca Plc | 259,526 | 706,847 | 123,141 |
| PEERS TOTAL | 3,419,086 | 954,802 | 160,899 |
Sign in to see all peers for Spyre Therapeutics Inc .
Spyre Therapeutics Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Eli Lilly And Company | United States 61.21 % |
| Beone Medicines Ltd | United States 51.69 % |
| Pfizer Inc | United States 58.91 % |
| Bristol myers Squibb Company | United States 67.79 % |
| Teva Pharmaceutical Industries Limited | Europe 30.49 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Spyre Therapeutics Inc .
Spyre Therapeutics Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 498 companies in Spyre Therapeutics Inc's industry classification, broader than the peer set above. Market cap in millions of $.Spyre Therapeutics Inc ranks #20 of 498 companies by market capitalization in its industry, holding 0.54 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 827, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,062,533 | 19.39 % |
| 2 | Johnson and Johnson | 664,610 | 12.13 % |
| 3 | Beone Medicines Ltd | 545,679 | 9.96 % |
| 4 | Abbvie Inc | 467,633 | 8.54 % |
| 5 | Merck and Co Inc | 1,234 | 5.2% |
| 6 | Novartis Ag | 1,234 | 5.2% |
| 7 | Abbott Laboratories | 1,234 | 5.2% |
| 8 | Novo Nordisk A | 1,234 | 5.2% |
| 9 | Pfizer Inc | 1,234 | 5.2% |
| 10 | Vertex Pharmaceuticals Inc | 1,234 | 5.2% |
| 20 | Spyre Therapeutics Inc | 29,455 | 0.54 % |
Market cap and industry share for the rest of Spyre Therapeutics Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-09-28.
Spyre Therapeutics Inc's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 15 | Regeneron Pharmaceuticals Inc | 80,401 | 36.54 % |
| 16 | Teva Pharmaceutical Industries Limited | 44,806 | 109.48 % |
| 17 | Alnylam Pharmaceuticals Inc | 34,741 | -44.12 % |
| 18 | Royalty Pharma Plc | 32,417 | 66.79 % |
| 19 | Takeda Pharmaceutical Company Limited | 1,234 | 12.3% |
| 20 | Spyre Therapeutics Inc | 29,455 | 445.29 % |
| 21 | Zoetis Inc | 1,234 | 12.3% |
| 22 | Zai Lab Limited | 1,234 | 12.3% |
| 23 | Roivant Sciences Ltd | 1,234 | 12.3% |
| 24 | Insmed Inc | 1,234 | 12.3% |
| 25 | Alterity Therapeutics Limited | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Spyre Therapeutics Inc's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-09-28. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Spyre Therapeutics Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | - | - | - | - | - | - | - | - |
| Operating Margin | - | - | - | - | -3,640.23 % | - | - | - |
| Return on Invested Capital | -36.57 % | -49.68 % | -33.87 % | -29.68 % | -61.46 % | -336.20 % | -26.50 % | -19.77 % |
| P/E | - | - | - | - | - | - | 23.4x | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Spyre Therapeutics Inc's BCG Growth-Share Matrix
Relative market share (vs Spyre Therapeutics Inc's largest competitor by market cap) against industry revenue growth, using the standard textbook thresholds (1.0x share, 10% growth) a common framework, not a precision instrument.
Spyre Therapeutics Inc falls in the Dog quadrant: relative market share of 0.03x vs its largest competitor, in an industry growing revenue 8.0% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Spyre Therapeutics Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 827 (see Industry Market Structure & Concentration above) |
| Supplier Power | Not covered on this page | See Spyre Therapeutics Inc's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Spyre Therapeutics Inc's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Spyre Therapeutics Inc's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Spyre Therapeutics Inc falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Spyre Therapeutics Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Outperforming the U.S.A. 500 over the trailing 12 months.
Weaknesses
- Return on equity 41.6 points below the industry aggregate.
- Low relative market share vs the industry leader (0.03x).
Opportunities
- A meaningful share of tracked competitors (43.70 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Spyre Therapeutics Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Spyre Therapeutics Inc | 5.32 | 12.70 | - |
| Eli Lilly And Company | 0.20 | 1.48 | 1.59 |
| Beone Medicines Ltd | 2.30 | 3.16 | 0.23 |
| Abbvie Inc | 0.16 | 0.75 | - |
| Novartis Ag | 0.42 | 1.12 | 0.02 |
| Astrazeneca Plc | 0.19 | 0.94 | 0.51 |
Sign in to see all peers for Spyre Therapeutics Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Spyre Therapeutics Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Spyre Therapeutics Inc | Q2 2026 | - | - |
| Eli Lilly And Company | Q2 2026 | +47.7 % | +25.3 % |
| Beone Medicines Ltd | Q2 2026 | +29.7 % | +151.3 % |
| Abbvie Inc | Q2 2026 | +10.2 % | +284.3 % |
| Novartis Ag | Q4 2025 | +9.6 % | +17.0 % |
| Astrazeneca Plc | Q4 2025 | +8.6 % | +45.3 % |
| PEERS TOTAL | +12.3 % | +27.0 % |
Sign in to see all peers for Spyre Therapeutics Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Spyre Therapeutics Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Spyre Therapeutics Inc | Q2 2026 | - | - |
| Eli Lilly And Company | Q2 2026 | +33.5 % | +72.8 % |
| Beone Medicines Ltd | Q2 2026 | +6.4 % | -57.0 % |
| Abbvie Inc | Q2 2026 | -1.3 % | +19.7 % |
| Novartis Ag | Q4 2025 | +18.3 % | +13.3 % |
| Astrazeneca Plc | Q4 2025 | +11.2 % | +46.0 % |
Sign in to see all peers for Spyre Therapeutics Inc .
Spyre Therapeutics Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Spyre Therapeutics Inc | - | - | - |
| Eli Lilly And Company | 21.97% | 33.95% | 92.54% |
| Beone Medicines Ltd | 7.82% | 10.32% | 14.24% |
| Abbvie Inc | 4.68% | 9.11% | - |
| Novartis Ag | 12.59% | 12.62% | 30.00% |
| Astrazeneca Plc | 8.97% | 19.67% | 21.00% |
Sign in to see all peers for Spyre Therapeutics Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Spyre Therapeutics Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Spyre Therapeutics Inc | - | - |
| Eli Lilly And Company | 39.77 | 13.29 |
| Beone Medicines Ltd | 834.09 | 90.15 |
| Abbvie Inc | 75.22 | 7.32 |
| Novartis Ag | 20.53 | 5.07 |
| Astrazeneca Plc | 25.38 | 4.42 |
| PEERS AVERAGE | 43.53 | 7.32 |
Sign in to see all peers for Spyre Therapeutics Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.